Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 2/20 | 0.54 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.52 |
| ▸ | SELE | P16581 | 2/20 | 0.52 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.42 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.42 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5211808 | 0.90 | EDNRA (0.50) | EDNRAICAM1SELEVCAM1L3MBTL1 | |
| SCHEMBL5213212 | 0.90 | EDNRA (0.50) | EDNRAICAM1SELEVCAM1L3MBTL1 | |
| SCHEMBL8445138 | 0.89 | ICAM1 (0.67) | EDNRAICAM1SELEVCAM1L3MBTL1 | |
| SCHEMBL9374983 | 0.89 | EDNRA (0.50) | EDNRAKDM4EALDH1A1MAPTPLA2G10 | |
| SCHEMBL5211504 | 0.89 | EDNRA (0.48) | EDNRAICAM1SELEVCAM1L3MBTL1 | |
| SCHEMBL5210758 | 0.88 | ICAM1 (0.49) | EDNRAICAM1SELEVCAM1L3MBTL1 | |
| SCHEMBL30724572 | 0.87 | ICAM1 (0.58) | EDNRAICAM1SELEVCAM1L3MBTL1 | |
| SCHEMBL5212761 | 0.86 | ICAM1 (0.50) | EDNRAICAM1SELEVCAM1L3MBTL1 | |
| SCHEMBL5215758 | 0.86 | EDNRA (0.46) | EDNRAICAM1SELEVCAM1L3MBTL1 | |
| SCHEMBL5213792 | 0.86 | ICAM1 (0.46) | EDNRAICAM1SELEVCAM1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1636213-B1 | 3-ARYLOXY AND 3-HETEROARYLOXY SUBSTITUTED BENZO(B) THIOPHENES AS THERAPEUTIC AGENTS WITH PI3K ACTIVITY | WARNER LAMBERT CO (US) | 2007-06-13 | — | — | EP | disclosed |
| EP-1636213-A1 | 3-ARYLOXY AND 3-HETEROARYLOXY SUBSTITUTED BENZO(B) THIOPHENES AS THERAPEUTIC AGENTS WITH PI3K ACTIVITY | Warner-Lambert Company LLC (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20040259926-A1 | 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents | BRUENDL MICHELLE M (US) | 2004-12-23 | — | — | US | disclosed |
| WO-2004108715-A1 | 3-ARYLOXY AND 3-HETEROARYLOXY SUBSTITUTED BENZO(B) THIOPHENES AS THERAPEUTIC AGENTS WITH PI3K ACTIVITY | WARNER-LAMBERT COMPANY LLC (US) | 2004-12-16 | — | — | WO | disclosed |
| EP-0628038-B1 | 3-ALKYLOXY-, ARYLOXY-, OR ARYLALKYLOXYBENZO [b]THIOPHENE-2-CARBOXAMIDES AS INHIBITORS OF CELL ADHESION | WARNER LAMBERT CO (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0628038-A1 | 3-ALKYLOXY-, ARYLOXY-, OR ARYLALKYLOXYBENZO b]THIOPHENE-2-CARBOXAMIDES AS INHIBITORS OF CELL ADHESION | WARNER-LAMBERT COMPANY (US) | 1994-12-14 | — | — | EP | disclosed |
| US-5356926-A | Antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1994-10-18 | — | — | US | disclosed |
| EP-0299457-B1 | Novel benzothiophenes having antiallergic activity and both novel and other selected benzothiophenes having activity for treating acute respiratory distress syndrome | WARNER LAMBERT CO (US) | 1994-09-21 | — | — | EP | disclosed |
| WO-1993017008-A1 | 3-ALKYLOXY-, ARYLOXY-, OR ARYLALKYLOXYBENZO[b]THIOPHENE-2-CARBOXAMIDES AS INHIBITORS OF CELL ADHESION | WARNER-LAMBERT COMPANY (US) | 1993-09-02 | — | — | WO | disclosed |
| US-4931459-A | ADMINISTERING SUBSTITUTED BENZOTHIOPHENES OR BENZOFURANS | WARNER-LAMBERT COMPANY (US) | 1990-06-05 | — | — | US | disclosed |
| US-4910317-A | Containing a 5-amidetetrazole substitution in position 2 | WARNER-LAMBERT COMPANY (US) | 1990-03-20 | — | — | US | disclosed |
| EP-0299457-A2 | Novel benzothiophenes having antiallergic activity and both novel and other selected benzothiophenes having activity for treating acute respiratory distress syndrome | WARNER-LAMBERT COMPANY (US) | 1989-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259926-A1 | 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents | MALT1, CYP1B1, CYP4B1 | EDNRA 1664/4885ICAM1 1919/4885SELE 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.